Omeros Corporation

OMER • Biotechnology

$18.95

▼ -0.16 (-0.84%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$1.70B

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Liquidez saludable · 2.76Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:10 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$18.95

Change-0.84%

Shares Out89.63M

Market Cap$1.70B

Enterprise Value$1.58B

52W Range3.94 - 18.14

Beta2.54

P/E13.61

P/S171.68

P/B-33.08

P/FCF9.92

EV/Sales159.40

Price$18.95

Change-0.84%

Shares Out89.63M

Market Cap$1.70B

Enterprise Value$1.58B

52W Range3.94 - 18.14

Beta2.54

P/E13.61

P/S171.68

P/B-33.08

P/FCF9.92

EV/Sales159.40

EV/EBITDA-21.87

EV/FCF9.21

Earnings Yield7.35%

FCF Yield10.08%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq-1.97

Current Ratio2.76

Quick Ratio2.76

Target$33.00

Target Upside74.14%

Target Median$33.00

Target Range33.00 - 33.00

Volume13.36M

Avg Volume1.69M

EPS Surprise0.16

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

50/100

Por qué este puntaje▼

Liquidez saludable · 2.76Rentabilidad débil

Analyst view

Analyst sentiment and price target

OMER

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

74/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$33.00

Promedio

$33.00

Mediana

$33.00

Alto

$33.00

Resumen de la compañía

IPO: 10/8/2009

Industria: Biotechnology

P/B i: -33.08

Deuda / Patrimonio i: -1.97

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: -1.97

Ratio corriente: 2.76

Ratio rápido: 2.76

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 2 venta interna de alto volumens detectadas

Borges David J.

Transacción: 07/22/2026

COMPRA

Cambio

+105,000

Precio

$9.84

Presentación

07/24/2026

Tipo

COMPRA

Cancelmo Peter B

Transacción: 07/22/2026

COMPRA

Cambio

+105,000

Precio

$9.84

Presentación

07/24/2026

Tipo

COMPRA

Demopulos Gregory A MD

Transacción: 07/22/2026

COMPRA

Cambio

+1,000,000

Precio

$9.84

Presentación

07/24/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Borges David J.	COMPRA	+105,000	$9.84	07/22/2026	07/24/2026
Cancelmo Peter B	COMPRA	+105,000	$9.84	07/22/2026	07/24/2026
Demopulos Gregory A MD	COMPRA	+1,000,000	$9.84	07/22/2026	07/24/2026
Bumol Thomas F.	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
Cable Thomas J.	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
Demopulos Peter A MD	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
HANISH ARNOLD C	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
Hood Leroy E. MD PhD	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
Perkinson Diana T.	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
Shah Rajiv	COMPRA	+15,000	$10.28	06/18/2026	06/22/2026
Cable Thomas J.	VENTA	-7,500	$10.84	05/22/2026	05/27/2026
Cable Thomas J.	VENTA	-7,500	$11.61	05/22/2026	05/27/2026
Demopulos Gregory A MD	VENTA	-400,000	$10.27	02/18/2026	02/20/2026
Demopulos Gregory A MD	VENTA	-357,678	$11.93	02/18/2026	02/20/2026
Borges David J.	VENTA	-30,000	$12.31	01/13/2026	01/14/2026
Borges David J.	VENTA	-30,000	$3.06	01/13/2026	01/14/2026
Borges David J.	VENTA	-30,000	$12.72	01/12/2026	01/14/2026
Demopulos Gregory A MD	COMPRA	+300,000	Not reported	10/13/2025	10/15/2025
Borges David J.	COMPRA	+95,000	$3.20	06/30/2025	07/01/2025
Cancelmo Peter B	COMPRA	+100,000	$3.20	06/30/2025	07/01/2025

Sobre la compañía

Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Fuente - Link

Competidores

ADCT BCYC FDMT FULC GOSS KALV LXRX NMRA OCGN RAPT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER

BlackRock Inc. purchased a new stake in Omeros Corporation (NASDAQ: OMER) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,044,633 shares of the biopharmaceutical company's stock, valued at approximately $57,484,000. BlackRock Inc. owned approximately 8.35% of Omeros at the end

Defense World

What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Zacks Investment Research

Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the

Defense World

Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript

Seeking Alpha

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.4	-0.24	0.16
2026-03-31	-0.55	3.14	3.69
2025-11-13	-0.58	-0.19	0.39
2025-08-14	-0.55	-0.53	0.02
2025-05-15	-0.57	-0.65	-0.08
2025-03-31	-0.78	-0.63	0.15
2024-11-13	-0.7	-0.64	0.06
2024-08-07	-1.14	-1.12	0.02
2024-05-15	-0.58	-0.74	-0.16
2024-04-01	-0.56	-0.63	-0.07
2023-11-09	-0.62	-0.82	-0.2
2023-08-09	-0.6	-0.7	-0.1